Telephone
61.3.9826.0399
Address
Level 4 Suite 0403 650 Chapel Street South Yarra, Victoria (VIC) 3141
Description
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.29 - 0.75
Trade Value (12mth)
AU$110,537.00
1 week
6.58%
1 month
12.5%
YTD
-22.17%
1 year
-16.7%
All time high
3.60
EPS 3 yr Growth
611.700%
EBITDA Margin
%
Operating Cashflow
-$179m
Free Cash Flow Return
-586.90%
ROIC
-693.50%
Interest Coverage
-11.20
Quick Ratio
5.20
Shares on Issue (Fully Dilluted)
643m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.08
Date | Announcements |
---|---|
19 July 24 |
Change in substantial holding
×
Change in substantial holding |
19 July 24 |
Change in substantial holding
×
Change in substantial holding |
18 July 24 |
Opthea Welcomes Retina Leaders to its Medical Advisory Board
×
Opthea Welcomes Retina Leaders to its Medical Advisory Board |
17 July 24 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
17 July 24 |
OPTOB - Range of Units
×
OPTOB - Range of Units |
17 July 24 |
OPTOB Top Holders
×
OPTOB Top Holders |
17 July 24 |
Security Class Reinstatement to Quotation- OPTOB
×
Security Class Reinstatement to Quotation- OPTOB |
15 July 24 |
Opthea Announces Results of Retail Entitlement of A$55.9m
×
Opthea Announces Results of Retail Entitlement of A$55.9m |
11 July 24 |
Security Class Suspension from Quotation OPTOB
×
Security Class Suspension from Quotation OPTOB |
10 July 24 |
Opthea Announces Publication on VEGF- C and D
×
Opthea Announces Publication on VEGF- C and D |
25 June 24 |
Change in substantial holding
×
Change in substantial holding |
25 June 24 |
Change in substantial holding
×
Change in substantial holding |
21 June 24 |
Opthea Cleansing Statement
×
Opthea Cleansing Statement |
20 June 24 |
Application for quotation of securities - OPT
×
Application for quotation of securities - OPT |
19 June 24 |
Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens
×
Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens |
14 June 24 |
Opthea Completes Placement & Institutional Entitlement Offer
×
Opthea Completes Placement & Institutional Entitlement Offer |
12 June 24 |
Trading Halt - Accelerated Offer
×
Trading Halt - Accelerated Offer |
12 June 24 |
Opthea Annouces Equity Raise
×
Opthea Annouces Equity Raise |
12 June 24 |
Opthea Equity Raise Investor Presentation
×
Opthea Equity Raise Investor Presentation |
12 June 24 |
Opthea - Prospectus 2024
×
Opthea - Prospectus 2024 |
12 June 24 |
Proposed issue of securities - OPT
×
Proposed issue of securities - OPT |
12 June 24 |
Update - Proposed issue of securities - OPT
×
Update - Proposed issue of securities - OPT |
07 June 24 |
Trading Halt
×
Trading Halt |
03 June 24 |
Opthea to Present at Clinical Trials at the Summit Meeting
×
Opthea to Present at Clinical Trials at the Summit Meeting |
28 May 24 |
Opthea Completes Enrollment in Phase 3 Clinical Program
×
Opthea Completes Enrollment in Phase 3 Clinical Program |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.